 Merck Co Inc NYSE: MRK has extended the research term by two years for the first cytokine derivative program under a 2018 agreement with Sutro Biopharma Inc NASDAQ: STRO. The research extension is intended to facilitate preclinical research and development activities for a second candidate with a novel design and approach. 